01 April 2023 → 30 September 2024
Regional and community funding: Industrial Research Fund
Medical and health sciences
Engineering and technology
- Medical biotechnology not elsewhere classified
single-domain antibodies human parainfluenzavirus cotton rat model
Human parainfluenza viruses (hPIVs) are a major cause of severe respiratory disease in (very) young children and the immunocompromised. hPIVs are the second main cause of hospitalization due to acute respiratory tract infection in children under five (respiratory syncytial virus ranks first). There are no clinically approved vaccines or antivirals available against hPIVs to prevent or treat these infections. Our group recently isolated antibodies that can neutralize hPIVs. In this project we aim to generate data to support the clinical potential of these antibodies.